PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.